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Abstract
Background: Respiratory syncytial virus is the most important pathogen in lower respiratory tract infection in infants 
and young children. In high-risk populations it may develop severe, sometimes fatal, lower respiratory tract infections. 
A proportion of these infants require admission to intensive care units due to the severity of the condition and the level 
of care needed. Furthermore, we must consider the possible increased risk of asthma following RSV infection in infancy.
Methods: The aim of this work is to show how we strictly coordinated, during the 2008-2009 RSV season, the delivery 
of prophylaxis while minimising drug cost through vial sharing and cohorting infants with a software performed 
through Visual Basic programming system.
Results: By using this method we have been able to obtain a saving of the 29.2% compared to the theoretical amount. 
No infant requested hospitalisation for a RSV infection.
Conclusions: Such a model ensures all patients to receive appropriate immunization and thus positively influencing 
the cost-benefit of palivizumab prophylaxis. We hope that our model of care delivery will be of use to other hospitals.
Introduction
Respiratory syncytial virus (RSV) is the most important
pathogen in lower respiratory tract infection in infants
and young children [1]. It causes coughs and colds in win-
ter season. The virus belongs to the same family as the
human parainfluenza viruses and mumps and measles
viruses. By 2 years of age, approximately 80% to 90% of
children experience at least one episode of RSV infection.
Although the majority of RSV infections are mild, high-
risk populations such as premature infants (gestational
age < 33 weeks) or children with hemodynamically signif-
icant heart disease or with lung abnormalities or with
immunodeficiency may develop severe, and sometimes
fatal, lower respiratory tract infections [2]. In Italy, about
4-5000 RSV infected high-risk infants are hospitalized
every year. A proportion of these infants require admis-
sion to intensive care units due to the severity of the con-
dition and the level of care needed [3] and have higher
mortality rates than healthy infants.
Furthermore, as potential long-term sequelae, we must
consider the possible increased risk of asthma and aller-
gies following RSV infection in infancy and its impact on
life quality [4].
Palivizumab, an intramuscular humanized mouse
monoclonal antibody, is used to reduce the risk of hospi-
talization secondary to RSV infection [5]. Seasonal pro-
phylaxis with this antibody demonstrated clinical efficacy
and satisfactory tolerability and it doesn't interfere with
the administration of other vaccines [6,7].
The aim of this work is to show how we strictly coordi-
nated, during the 2008-2009 RSV season, the delivery of
prophylaxis while minimising drug cost through vial
sharing.
Materials and Methods
The 2008-2009 RSV prophylaxis started in November
2008 and ended in April 2009. The vaccination program
was designed to ensure that every eligible infant received
RSV prophylaxis and his or her parents received neces-
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sary education to prevent RSV-related hospitalisation.
The 4 bed UTIN unit at "Barone I. Romeo" Hospital, Patti
(Messina) accepts 249 admissions per year. During the
RSV prophylaxis season to 24 high-risk eligible children
was administred the prophylaxis with palivizumab. High-
risk criteria indicating the prophylaxis are reported in
Table 1. The current recommended palivizumab dosage
is 15 mg/kg intramuscular injections (once per month for
a total of 5-6 doses during the RSV season). The cost of
50 mg and 100 mg vials of Synagis® (Abbott Laboratories
Limited) were 490.37€ and 814.35€ respectively. Synagis
requires storage in a refrigerator (2 to 8°C) and once
reconstituted, the palivizumab shelf life is estimated at six
hours [8] and multidose use of single-use vials is proven
safe [9].
We used a collaborative framework for the delivery of
RSV prophylaxis. The multidisciplinary team (pharma-
cists, physicians, nurses) collaborated to create a RSV
prophylaxis program logic model, ensuring that each dis-
cipline's perspective of the program process was consid-
ered. For each program component, the team identified
process and program objectives and outcomes.
Before the beginning of the prophylaxis all infants were
visited and weighted and the obtained data were recorded
on a database. In order to start the administration infants
were grouped in four cohorts of five and one of four with
a software performed by Coppolino S. through Visual
Basic programming system. Visual basic is used to write
Windows-based computer programs; by doing so you are
not bound by the limitations of a particular "off-the shell"
computer program. What is more you are able to design
applications to meet your own specific needs [10].
This software requests only to insert infants names and
their weight. By the clicking of a button the software cal-
culates the palivizumab dosage, in mg, to be adminis-
trated to each infant, and following to the vial selected (50
mg or 100 mg one) automatically divide infants in groups,
evidenced by different colours, to use as few vials as pos-
sible to minimise waste (Fig. 1). Children marked with the
same colour were scheduled to be vaccinated within the
same day.
All data were automatically collected in a ".txt" file cre-
ated to generate reports to be analysed afterwards with
common softwares.
For each dose, infants attended the Ambulatory Ward
on five consecutive afternoons. The second dose was
administred after 3 weeks and subsequent ones at 4
weekly intervals. In total 6800 mg were bought and 6200
mg were given to patients. During the season, adverse
events following immunization did not occur.
Results
All infants successfully completed their full course of RSV
prophylaxis and were followed for 150 days after the last
scheduled injection. No one requested hospitalisation for
RSV infection.
Table 1: High-risk criteria
Evidence grade I: Infants born from 32 weeks of gestation 
or earlier to 12 months at the beginning 
of RSV season.
Evidence grade I: Infants and children younger than 24 
months with CLD who required medical 
therapy (supplemental oxygen and/or 
drugs).
Evidence grade I: 24 months old or younger children 
receiving medication to control 
hemodybamically significant heart 
disease or diagnosed with moderate to 
severe pulmonary hypertension or 
diagnosed with cyanotic heart disease.
Evidence grade III: Infants, born at 32 to less 35 weeks of 
gestation, who are 12 months old, or 
younger, at the start of RSV season with 
at least two of the following risk factors: 
low weight at birth (<2.5 Kg), exposure 
to environmental air pollutants or 
tobacco smoke, lack of breast-feed, twin 
birth, chest malformation, hematologic 
diseases, cystic fibrosis, school-aged 
siblings, congenital abnormalities of the 
airways, cancer, severe neuromuscular 
diseases, immunodefiency or living 
where the access to a hospital is difficult.
Figure 1 screen of the developed software. This figure shows the 
main screen of the software used to schedule young patients during 
treatment It automatically evaluated the amount of drug to be admin-
istered and then it sorts infants by weight suggesting the best way to 
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We calculated theoretical vial usage if every infant had
been individually dosed with one vial and compared this
with our real use, obtained by using the cohorting soft-
ware and vial sharing. The aggregate seasonal drug cost
for the season was 56.706,92€ instead of 80.087.19€ with
a saving of 23.380,17€ (29.2% of theoretical amount). At
the individual partecipant level the average seasonal
palivizumab prophylaxis cost was 2372,69€. All data are
reported in Table 2.
Discussion
During all past seasonal prophylaxis with palivizumab we
treated an almost constant number of high-risk eligible
children for every year.
By using vial sharing and the above described software
we obtained a drug cost saving of 25% compared to 2007-
2008 season. Regarding the 2009-2010 campaign, in
which we used vial sharing and software again, the cost
saving was of about 2%, more or less the same of 2008-
2009 season and linked to the children weight.
There are main other considerations besides costs in
clinical decision making, but the careful use of resources
must always be considerated.
In-hospital interdisciplinary communication and work-
ing relationships were a program strength point, particu-
larly the relationship between pharmacy and " Pediatria e
UTIN" staff. This strength was attributed to the ongoing
opportunity for dialogue.
Like any expensive healthcare intervention, palivi-
z u m a b  i m m u n i z a t i o n  m u s t  b e  u s e d  j u d i c i o u s l y .  O u r
experience shows that it is possible to minimise the cost
by an accurate cohorting and by multidose distribution
with a maximising use of 100 mg vials in preference to the
more expensive 50 mg vials for cost saving with no
increased risk to patients. This does, however, required
tight coordination between hospital pharmacist and ward
and patient selection to discard ineligible children.
Conclusions
The use of palivizumab can be optimized through a
model in which children are prospectively identified and
vials are shared. Such a model ensures all patients to
receive appropriate immunization and thus positively
influencing the cost-benefit of palivizumab prophylaxis.
W e  h o p e  t h a t  o u r  m o d e l  o f  c a r e  d e l i v e ry  t o  h i g h - r i s k
infants will be of use to other hospitals who seek to opti-
mise delivery of their RSV immunization programs.
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Table 2: Use of palivizumab and resources saving during 2008-2009 campaign
Theoretical single use Real use with vial sharing Saving
50 mg vials 67 16 51
100 mg vials 58 60 -2
mg wasted 3.176,88 777,08 2.399,80
Value 80.087,09€ 56.706,92€ 23.380,17€